Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOVE3 (also referred to as ES-OM3) is a nutraceutical dietary supplement combination developed through a strategic partnership between Stratum Nutrition and KD Pharma. The formulation consists of 500 mg of NEM brand eggshell membrane combined with 1,500 mg of KD-Pür brand fish oil concentrate, providing a unique blend of naturally occurring glycosaminoglycans, proteins, and omega-3 fatty acids (specifically eicosapentaenoic acid and docosahexaenoic acid). MOVE3 is designed to support joint health by targeting inflammatory pathways and reducing cartilage degradation. Clinical studies in healthy adults have demonstrated that the supplement significantly reduces joint pain and stiffness both immediately and 12 hours after exercise. It also acts by lowering levels of C-terminal cross-linked telopeptide of type-II collagen (CTX-II), a key biomarker for cartilage turnover and degradation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eggshell membrane + fish oil.